ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2022 - 2025)

ProQR Therapeutics (PRQR) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 4.37% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 4.37% year-over-year, with the annual reading at $3.3 million for FY2025, 4.37% down from the prior year.
  • Long-Term Deferred Tax hit $3.3 million in Q4 2025 for ProQR Therapeutics, down from $3.5 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $4.3 million in Q4 2023 to a low of $3.3 million in Q4 2025.
  • Historically, Long-Term Deferred Tax has averaged $3.8 million across 4 years, with a median of $3.7 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: increased 7.13% in 2023 and later dropped 18.73% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $4.0 million in 2022, then increased by 7.13% to $4.3 million in 2023, then decreased by 18.73% to $3.5 million in 2024, then fell by 4.37% to $3.3 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for PRQR at $3.3 million in Q4 2025, $3.5 million in Q4 2024, and $4.3 million in Q4 2023.